New Study Explores if a Vaccine Can Prevent Breast Cancer
Harnessing the immune system to target cancer has long resided on doctors’ wish lists, with very little promise of becoming reality. Because cancer cells are normal cells that mutate to grow out of control, directing the body to destroy these cells is a risky endeavor with potentially dangerous outcomes.
Advances in immunotherapy, however, have led to powerful drugs that can help immune cells better distinguish between cancer cells and healthy ones, and researchers are now testing the idea of whether the immune system can be trained to recognize and destroy breast cancer cells in the same way that it dispatches virus...
Source: TIME: Health - November 29, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer healthscienceclimate Source Type: news
Implementing ADCs in HER2-Positive Breast Cancer Implementing ADCs in HER2-Positive Breast Cancer
Learn more about the antibody-drug conjugates currently approved as well as those under development for the treatment of HER2-positive breast cancer.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 4, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Ultrasound Enhances Drug Delivery to Treat Brain Metastases Ultrasound Enhances Drug Delivery to Treat Brain Metastases
Proof-of-concept study shows MR-guided focused ultrasound enhances drug delivery to better treat brain metastases in HER2+ breast cancer patients.Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - October 14, 2021 Category: Radiology Tags: Hematology-Oncology News Source Type: news
FDA Approves Verzenio(R) (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
Adding Verzenio to endocrine therapy demonstrated a significant and clinically meaningful reduction in the risk of recurrence in patients with HR+ HER2-, node-positive, high risk early breast cancer and a Ki-67 score of ≥20%
Verzenio is the first ... Biopharmaceuticals, Oncology, FDA Eli Lilly, Verzenio, abemaciclib, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 13, 2021 Category: Pharmaceuticals Source Type: news
Breakthroughs in Metastatic Breast Cancer From ESMO 2021 Breakthroughs in Metastatic Breast Cancer From ESMO 2021
Dr Javier Cortes presents practice-changing data on metastatic breast cancer from ESMO 2021, including trastuzumab deruxtecan in HER2+ disease, pembrolizumab in TNBC, and ribociclib in HR+/HER2- disease.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 8, 2021 Category: Consumer Health News Tags: None ReCAP Source Type: news
Once-Daily Poziotinib Shows Efficacy in NSCLC HER2 Exon 20 Once-Daily Poziotinib Shows Efficacy in NSCLC HER2 Exon 20
The drug showed clinically meaningful efficacy for patients with treatment-naive nonsmall cell lung cancer HER2 exon 20 mutations.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 29, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Trastuzumab Deruxtecan Slows Metastatic Breast Cancer
Progression - free survival longer with T - DXd versus T - DM1 for HER2+ metastatic breast cancer previously treated with trastuzumab and taxane (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 24, 2021 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news
' Astonishing' PFS Improvement in Metastatic HER+ Breast Cancer'Astonishing' PFS Improvement in Metastatic HER+ Breast Cancer
Experts hail the"astonishing" improvement in progression-free survival reported with trastuzumab deruxtecan in HER2+ metastatic breast cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 22, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Six Months of Trastuzumab Effective in HER2+ Breast Cancer Six Months of Trastuzumab Effective in HER2+ Breast Cancer
A large-scale data analysis has confirmed that 6 months of trastuzumab is just as effective as 12 months in HER2+ early breast cancer, but the question is whether it will be adopted, say experts.Medscape News UK (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 20, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Roche presents first phase II data on giredestrant, a next generation selective oestrogen receptor degrader, in untreated oestrogen receptor (ER)-positive, early breast cancer
Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced interim data from the randomised phase II coopERA Breast Cancer trial evaluating neoadjuvant treatment with giredestrant (formerly known as GDC-9545), an investigational next generation oral selective oestrogen receptor degrader (SERD), in post-menopausal women with ER-positive, HER2-negative early breast cancer. In the window of opportunity phase, after 14 days of treatment, giredestrant showed a reduction in Ki67, a prognostic marker that measures tumour proliferation, compared to anastrozole (80% versus 67% respectively, p=0.0222). The safety ...
Source: Roche Investor Update - September 17, 2021 Category: Pharmaceuticals Source Type: news
Neoadjuvant pertuzumab a costly addition for treating HER2+ breast cancer in Portugal
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - September 1, 2021 Category: Drugs & Pharmacology Source Type: news
ASCO Updates Recommendations for Managing Hereditary Breast Cancer
FRIDAY, July 9, 2021 -- One year of adjuvant olaparib should be offered to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 9, 2021 Category: Pharmaceuticals Source Type: news
Adding checkpoint inhibition to anti-HER2 breast cancer therapy brings no benefit
(European Society for Medical Oncology) Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary. The phase III trial is the first to report data comparing a neoadjuvant anti-HER2 based regimen with or without the anti-PD-L1 antibody atezolizumab in patients with high-risk, HER2-positive early breast cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 17, 2021 Category: International Medicine & Public Health Source Type: news
Olaparib Beneficial for BRCA-Mutated HER2-Negative Breast Cancer Olaparib Beneficial for BRCA-Mutated HER2-Negative Breast Cancer
Dr Kathy Miller shares the ' biggest news in the breast cancer world ' from ASCO, with presented data showing the benefit of olaparib in patients with high-risk,BRCA-mutated HER2-negative disease.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 12, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
FDA approves margetuximab for metastatic HER2-positive breast cancer
On December 16, 2020, FDA approved margetuximab-cmkb (MARGENZA, MacroGenics) in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
